

Hassane M Zarour

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8390065/hassane-m-zarour-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

1,735
citations

15
h-index

29
g-index

29
ext. papers

2,520
ext. citations

10.1
avg, IF

5.45
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 22 | Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1600-9 | 27.4 | 666 |
| 21 | Reversing T-cell Dysfunction and Exhaustion in Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1856-64 | 12.9 | 216 |
| 20 | Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. <i>Science</i> , 2021 , 371, 595-602 | 33.3 | 211 |
| 19 | Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 1845-55 | 12.9 | 172 |
| 18 | TIGIT in cancer immunotherapy 2020 , 8, | | 129 |
| 17 | IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. <i>Cancer Research</i> , 2015 , 75, 1635-44 | 10.1 | 97 |
| 16 | IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5520-5533 | 12.9 | 40 |
| 15 | Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , JCO1800632 | 2.2 | 33 |
| 14 | IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. <i>Cancer Immunology Research</i> , 2019 , 7, 1258-1266 | 12.5 | 29 |
| 13 | Immunotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014 , 3, 2-14 | 4.4 | 24 |
| 12 | Cancer immunotherapy: Progress and challenges in the clinical setting. <i>European Journal of Immunology</i> , 2011 , 41, 1510-5 | 6.1 | 23 |
| 11 | Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.. <i>Nature Medicine</i> , 2022 , | 50.5 | 19 |
| 10 | Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3054-3054 | 2.2 | 16 |
| 9 | Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9572-9572 | 2.2 | 5 |
| 8 | Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors. <i>Methods in Molecular Biology</i> , 2020 , 2055, 23-60 | 1.4 | 5 |
| 7 | Targeting novel inhibitory receptors in cancer immunotherapy. <i>Seminars in Immunology</i> , 2020 , 49, 101436 | 6.7 | 3 |
| 6 | A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. <i>OncImmunology</i> , 2021 , 10, 1898105 | 7.2 | 2 |

| | | | |
|---|---|-----|---|
| 5 | Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9579-9579 | 2.2 | 1 |
| 4 | The cancer-germline antigen TRAG-3 stimulates Th1-type, Toll-like receptor 8-negative antigen-specific CD4+ regulatory T cells. <i>FASEB Journal</i> , 2008 , 22, 1079.19 | 0.9 | |
| 3 | Upregulation of PD-1 expression on tumor antigen-specific CD8+ T cells in patients with advanced melanoma is associated with reversible immune dysfunction. <i>FASEB Journal</i> , 2008 , 22, 1077.21 | 0.9 | |
| 2 | Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15175-e15175 | 2.2 | |
| 1 | The microbiome: a basis for novel immunomodulation in mice and men. <i>Clinical Advances in Hematology and Oncology</i> , 2017 , 15, 535-536 | 0.6 | |